What is Agenus's market cap?

Agenus (AGEN) has a market capitalization of $371.3M and trades on NASDAQ.

Who are Agenus's competitors?

Agenus's key competitors include Novavax, Bristol Myers Squibb, Merck & Co., and others. These companies compete in similar markets and product categories.

Who does Agenus partner with?

Agenus's notable partners include Zydus Lifesciences Ltd., Merck & Co., Bristol Myers Squibb, and others.

What subsidiaries does Agenus have?

Agenus's subsidiaries include SaponiQx, Inc., MiNK Therapeutics, Inc..

Where is Agenus headquartered?

Agenus is headquartered in United States of America and employs approximately 389 people. It has been publicly traded since 2000.

Agenus (AGEN) Stock Fundamentals & Financials

Agenus Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of immunotherapies for cancer and infectious diseases.

Market cap

$371.33M+157%

Earnings

Q2 2026 report

August 6, 2026

Revenue$34.5MBeat by $500.0K EPS-$0.01Miss by $0.06

Read the full report

Next report

Nov 9, 2026 (in 2 months)

Revenue estimate$35.0M

EPS estimate$0.02

Competitors

By market cap

Merck & Co.$377.72B+79.9%

Bristol-Myers Squibb$138.03B+42.4%

ImmunityBio, Inc.$8.7B+295%

Novavax$1.5B+23.4%

Agenus$371.3M+157%

OS Therapies$76.7M-3.8%

Xilio Therapeutics, Inc.$59.6M+67.8%

AIM ImmunoTech$7.6M+12.4%

By revenue growth

ImmunityBio, Inc.+352%

Merck & Co.+4.6%

Bristol-Myers Squibb+3.1%

Novavax-61.6%

By net margin

Bristol-Myers Squibb18.87%+8.4pp

Merck & Co.4.77%-21.0pp

Novavax-59.87%-99.1pp

ImmunityBio, Inc.-606.15%+704pp

Profile

Agenus Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of immunotherapies for cancer and infectious diseases. The company's core value proposition centers on its immuno-oncology platform, which utilizes antibody-based programs to activate the immune system and overcome tumor evasion. Its primary focus is advancing its lead combination therapy, botensilimab and balstilimab, across multiple refractory solid tumor types.

Competitive position

A clinical-stage developer focused on 'next-generation' CTLA-4 and PD-1 therapies, utilizing early access programs in Europe to generate initial revenue while pursuing registrational trials.

GeographiesUnited States, France, Canada, Australia, New Zealand

Customer segmentsPharmaceutical companies, Hospitals, National health systems

Business modelR&D-stage biotechnology, Licensing and Royalties, Strategic Collaborations

SuppliersContract research organizations, Academic research institutions, Raw material suppliers for saponin extraction, Biologics manufacturing partners

CustomersNational health systems (e.g., France's AAC program), Global pharmaceutical companies, Clinical trial participants, Specialty pharmacies

CountryUnited States of America

Listed2000

Employees389.0

CEOGaro H. Armen

SectorHealthcare

IndustryBiotechnology

Websiteagenusbio.com

FilingsSEC EDGAR

FAQ

What is Agenus's market cap?: Agenus (AGEN) has a market capitalization of $371.3M and trades on NASDAQ.
Who are Agenus's competitors?: Agenus's key competitors include Novavax, Bristol Myers Squibb, Merck & Co., and others. These companies compete in similar markets and product categories.
Who does Agenus partner with?: Agenus's notable partners include Zydus Lifesciences Ltd., Merck & Co., Bristol Myers Squibb, and others.
What subsidiaries does Agenus have?: Agenus's subsidiaries include SaponiQx, Inc., MiNK Therapeutics, Inc..
Where is Agenus headquartered?: Agenus is headquartered in United States of America and employs approximately 389 people. It has been publicly traded since 2000.